The IHC surrogate of molecular subtype, based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) receptor status, is one of the most clinically relevant primary breast cancer tumor characteristics. This evidence concerns the gene ERBB2 and breast carcinoma.